Dr. Rinn and his colleagues have discovered a new class of molecule that may have important implications for understanding and treating cancer. lincRNAs large intergenic non-coding RNAs are unique from other materials in cells, however, their precise function remains unknown. Dr. Rinn aims to decipher the workings of lincRNAs and proposes based on his pioneering early research - that they may have a role in tumor formation. His work could lead to new ways to diagnose and target multiple cancer types.
Dr. Rinn said, "It is truly an honor to be recognized by a scientific organization as storied as the Damon Runyon Cancer Research Foundation, especially as it appreciates the value in taking big risks for big rewards. Being granted this Award is like winning the Super Bowl for a young scientist starting a lab!"
Funding Daring Research
Debbie and Andy Rachleff partnered with the Damon Runyon Cancer Research Foundation to create the Innovation Award in 2007.
Andy Rachleff commented, "We're thrilled with the caliber of the people and the proposals received this year. A large number of young investigators submitted applications that proposed to take significant risks in order to achieve breakthroughs in the prevention, diagnosis and treatment of cancer. As a venture capitalist, I look for visionaries with daring ideas. It is exciting to see these qualities in all of the winning proposals.
"Scientists at this stage of their career often struggle to gain funding for any out-of-the-box ideas, even if they have huge potential. This is in direct contrast to venture capital funding, where young people are recognized as being the most likely to make breakthroughs. This Award was designed to address this incongruity."
Lorraine Egan, Executive Director of the Damon Runyon Cancer Research Foundation, added, "Most research funded today is safe and incremental. For large breakthro
|Contact: Yung S. Lie, Ph.D.|
Damon Runyon Cancer Research Foundation